The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

ElevateBio has entered into a multi-year collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

The firms are combining forces to get their cancer screening and diagnostic platforms into more hospitals in the US.

Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...

The first patient, who had xerostomia linked with Sjögren's disease, received the autologous cell therapy as part of a Phase ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...